Vanguard Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,076,789
| Closed | -$2.86M | – | 4507 |
|
|
2024
Q1 | $2.86M | Buy |
1,076,789
+33,879
| +3% | +$83.9K | ﹤0.01% | 3481 |
|
|
2023
Q4 | $2.47M | Buy |
1,042,910
+48,698
| +5% | +$86.2K | ﹤0.01% | 3529 |
|
|
2023
Q3 | $1.39M | Hold |
994,212
| – | – | ﹤0.01% | 3720 |
|
|
2023
Q2 | $3.01M | Sell |
994,212
-30,474
| -3% | -$117K | ﹤0.01% | 3518 |
|
|
2023
Q1 | $6.4M | Buy |
1,024,686
+6,746
| +0.7% | +$41.1K | ﹤0.01% | 3188 |
|
|
2022
Q4 | $6.21M | Buy |
1,017,940
+6,593
| +0.7% | +$53.7K | ﹤0.01% | 3199 |
|
|
2022
Q3 | $12.1M | Buy |
1,011,347
+15,270
| +2% | +$200K | ﹤0.01% | 2862 |
|
|
2022
Q2 | $12.6M | Sell |
996,077
-459,557
| -32% | -$4.28M | ﹤0.01% | 2865 |
|
|
2022
Q1 | $16.4M | Sell |
1,455,634
-466,789
| -24% | -$5.14M | ﹤0.01% | 2885 |
|
|
2021
Q4 | $34.1M | Buy |
1,922,423
+60,815
| +3% | +$1.28M | ﹤0.01% | 2558 |
|
|
2021
Q3 | $42.9M | Buy |
1,861,608
+672,778
| +57% | +$14.6M | ﹤0.01% | 2445 |
|
|
2021
Q2 | $27.7M | Sell |
1,188,830
-117,091
| -9% | -$2.98M | ﹤0.01% | 2676 |
|
|
2021
Q1 | $40.7M | Buy |
1,305,921
+454,083
| +53% | +$15.8M | ﹤0.01% | 2426 |
|
|
2020
Q4 | $33.9M | Buy |
+851,838
| New | +$34.2M | ﹤0.01% | 2389 |
|
Vanguard Group's KNTE Position: Q2 2024 in Review
Vanguard Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 1,076,789 shares — an estimated $2.86M sold.
Vanguard Group first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $42.9M in Q3 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Vanguard Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Vanguard Group sold 1,076,789 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $2.86M.
- Vanguard Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
- Vanguard Group's Kinnate Biopharma Inc. Common Stock position peaked at $42.9M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Vanguard Group's 13F filing for Q2 2024, filed 13 Aug 2024.